Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.70 |
| ▸ | RARB | P10826 | 12/20 | 0.67 |
| ▸ | RARG | P13631 | 12/20 | 0.67 |
| ▸ | RARA | P10276 | 11/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 5/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17885757 | 0.85 | CYP3A4 (0.71) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL9257862 | 0.85 | CYP3A4 (0.50) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL5485071 | 0.84 | CYP3A4 (0.70) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL6665694 | 0.84 | CYP3A4 (0.70) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL30374281 | 0.83 | CYP3A4 (0.69) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL860637 | 0.83 | CYP3A4 (0.69) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL14330777 | 0.83 | CYP3A4 (0.84) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotenic Acid SCHEMBL678713 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotenic Acid SCHEMBL29466098 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotenic Acid SCHEMBL29433140 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018218242-A1 | METHODS AND COMPOSITIONS FOR COMBINATION THERAPY | EPICENTRX, INC. (US) | 2018-11-29 | — | — | WO | claimed |
| US-9107844-B2 | Topical skin treating compositions | STIEFEL LABORATORIES INC. (US) | 2015-08-18 | — | — | US | claimed |
| US-20120259014-A1 | TOPICAL RETNOID SOLUTIONS | RANBAXY LABORATORIES LIMITED (IN) | 2012-10-11 | — | — | US | claimed |
| EP-2432453-A2 | TOPICAL RETINOID SOLUTIONS | Ranbaxy Laboratories Limited (IN) | 2012-03-28 | — | — | EP | claimed |
| WO-2010134048-A2 | TOPICAL RETINOID SOLUTIONS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-25 | — | — | WO | claimed |
| US-20090226380-A1 | Topical Skin Treating Compositions | STIEFEL LABORATORIES INC. | 2009-09-10 | — | — | US | claimed |
| EP-1898896-A2 | TOPICAL SKIN TREATING COMPOSITIONS | STIEFEL LABORATORIES, INC. (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007092312-A2 | TOPICAL SKIN TREATING COMPOSITIONS | STIEFEL LABORATORIES, INC. (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070003585-A1 | Topical skin treating compositions | STIEFEL LABORATORIES, INC. (US) | 2007-01-04 | — | — | US | claimed |
| WO-2007002831-A2 | TOPICAL SKIN TREATING COMPOSTIONS | STIEFEL LABORATORIES, INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-5089509-A | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC. (US) | 1992-02-18 | — | — | US | claimed |
| US-20260014134-A1 | COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY | DAVIS ADRIAN (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4167959-B1 | COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY | LIMEWAY PHARMA DESIGN LTD (GB) | 2024-08-28 | — | — | EP | disclosed |
| US-20230210835-A1 | COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY | LIMEWAY PHARMA DESIGN LTD (GB) | 2023-07-06 | — | — | US | disclosed |
| US-11033567-B2 | 5-aza-2′-deoxycytidine and methods of use thereof for promoting wound healing and regeneration | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-06-15 | — | — | US | disclosed |
| US-5380877-A | Psoriasis treatment; retinoic acid-like activity | ALLERGAN, INC. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5354752-A | A dimethylthiochroman or dimethylchroman-6-yl-ethynyl-pyridazin- or pyrimidin- or pyrazin-for treating skin disorders psoriasis | ALLERGAN, INC. (US) | 1994-10-11 | — | — | US | disclosed |
| US-5348972-A | In treatment of skin disorders such as acne and psoriasis | ALLERGAN, INC. (US) | 1994-09-20 | — | — | US | disclosed |
| US-5234926-A | Skin disorders | ALLERGAN, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5089509-A | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC. (US) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014134-A1 | COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY | LRBA, DNER, KRT18 | CYP3A4 1969/4885CYP26A1 558/4885RARB 189/4885 |
| US-20230210835-A1 | COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY | CUTA, SGMS1, CERS2 | CYP3A4 1605/4885CYP26A1 568/4885RARB 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.